Christina Sophia Albott

Christina Sophia Albott

Auto-generated profile, based on publicly available information

Christina Sophia Albott

Department of Psychiatry and Behavioral Science, University of Minnesota Twin Cities

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
CACristina Sophia Albott
Cristina Sophia Albott
JWJeffrey R. Wozniak
Jeffrey R. Wozniak
BMBrian P. McGlinch
Brian P. McGlinch
MWMichael H. Wall
Michael H. Wall
BGBarbara S. Gold
Barbara S. Gold
SVSophia Vinogradov
Sophia Vinogradov
The outbreak of the coronavirus disease 2019 (COVID-19) and its rapid global spread have created unprecedented challenges to health care systems. Significant and sustained efforts have focused on mobilization of personal protective equipment, intensive care beds, and medical equipment, while substantially less attention has focused on preserving the psychological health of the medical workforce tasked with addressing the challenges of the pandemic. And yet, similar to battlefield conditions, health care workers are being confronted with ongoing uncertainty about resources, capacities, and risks; as well as exposure to suffering, death, and threats to their own safety. These conditions are engendering high levels of fear and anxiety in the short term, and place individuals at risk for persistent stress exposure syndromes, subclinical mental health symptoms, and professional burnout in the long term. Given the potentially wide-ranging mental health impact of COVID-19, protecting health care workers from adverse psychological effects of the pandemic is critical. Therefore, we present an overview of the potential psychological stress responses to the COVID-19 crisis in medical providers and describe preemptive resilience-promoting strategies at the organizational and personal level. We then describe a rapidly deployable Psychological Resilience Intervention founded on a peer support model (Battle Buddies) developed by the United States Army. This intervention—the product of a multidisciplinary collaboration between the Departments of Anesthesiology and Psychiatry & Behavioral Sciences at the University of Minnesota Medical Center—also incorporates evidence-informed “stress inoculation” methods developed for managing psychological stress exposure in providers deployed to disasters. Our multilevel, resource-efficient, and scalable approach places 2 key tools directly in the hands of providers: (1) a peer support Battle Buddy; and (2) a designated mental health consultant who can facilitate training in stress inoculation methods, provide additional support, or coordinate referral for external professional consultation. In parallel, we have instituted a voluntary research data-collection component that will enable us to evaluate the intervention’s effectiveness while also identifying the most salient resilience factors for future iterations. It is our hope that these elements will provide guidance to other organizations seeking to protect the well-being of their medical workforce during the pandemic. Given the remarkable adaptability of human beings, we believe that, by promoting resilience, our diverse health care workforce can emerge from this monumental challenge with new skills, closer relationships, and greater confidence in the power of community.

1 February 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
PSPaulo R Shiroma
Paulo R Shiroma
BJBrian Johns
Brian Johns
MKMichael Kuskowski
Michael Kuskowski
JWJoseph Wels
Joseph Wels
PTPaul Thuras
Paul Thuras
KLKelvin O. Lim
Kelvin O. Lim

27 June 2018 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
CAC. Sophia Albott
C. Sophia Albott
KLKelvin O. Lim
Kelvin O. Lim
MFMiriam K. Forbes
Miriam K. Forbes
CEChristopher Erbes
Christopher Erbes
STSusanna J. Tye
Susanna J. Tye
PSPaulo R. Shiroma
Paulo R. Shiroma
From The Journal of Clinical Psychiatry: Ketamine has shown promise in treating depression and posttraumatic stress disorder (PTSD) individually. This article examines repeated ketamine infusions for individuals with comorbid treatment-resistant depression and PTSD—read it to learn how efficacious this agent was for this patient group.

25 June 2014 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
PSPaulo R Shiroma
Paulo R Shiroma
CAC. Sophia Albott
C. Sophia Albott
BJBrian Johns
Brian Johns
PTPaul Thuras
Paul Thuras
JWJoseph Wels
Joseph Wels
KLKelvin O. Lim
Kelvin O. Lim
The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in treatment-resistant depression (TRD).

26 June 2020 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
PSPaulo R Shiroma
Paulo R Shiroma
PTPaul Thuras
Paul Thuras
JWJoseph Wels
Joseph Wels
CAC. Sophia Albott
C. Sophia Albott
CEChristopher Erbes
Christopher Erbes
KLKelvin O. Lim
Kelvin O. Lim
The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine. However, consensus guideline stated the lack of evidence to support frequent ketamine administration. We compared the efficacy and safety of single vs. six repeated ketamine using midazolam as active placebo. Subjects received either six ketamine or five midazolam followed by a single ketamine during 12 days followed by up to 6-month post-treatment period. The primary end point was the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at 24 h after the last infusion. Fifty-four subjects completed all six infusions. For the primary outcome measure, there was no significant difference in change of MADRS scores between six ketamine group and single ketamine group at 24 h post-last infusion. Repeated ketamine showed greater antidepressant efficacy compared to midazolam after five infusions before receiving single ketamine infusion. Remission and response favored the six ketamine after infusion 4 and 5, respectively, compared to midazolam before receiving single ketamine infusion. For those who responded, the median time-to-relapse was nominally but not statistically different (2 and 6 weeks for the single and six ketamine group, respectively). Repeated infusions were relatively well-tolerated. Repeated ketamine showed greater antidepressant efficacy to midazolam after five infusions but fell short of significance when compared to add-on single ketamine to midazolam at the end of 2 weeks. Increasing knowledge on the mechanism of ketamine should drive future studies on the optimal balance of dosing ketamine for maximum antidepressant efficacy with minimum exposure.

1 September 2018 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
KCKathryn R. Cullen
Kathryn R. Cullen
PAPalistha Amatya
Palistha Amatya
MRMark G. Roback
Mark G. Roback
CAChristina Sophia Albott
Christina Sophia Albott
MSMelinda Westlund Schreiner
Melinda Westlund Schreiner
BKBonnie Klimes-Dougan
Bonnie Klimes-Dougan
Background: Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors. Methods: Adolescents, 12–18 years of age, with TRD (failure to respond to two previous antidepressant trials) were administered six ketamine (0.5 mg/kg) infusions over 2 weeks. Clinical response was defined as a 50% decrease in Children's Depression Rating Scale-Revised (CDRS-R); remission was CDRS-R score ≤28. Tolerability assessment included monitoring vital signs and dissociative symptoms using the Clinician-Administered Dissociative States Scale (CADSS). Results: Thirteen participants (mean age 16.9 years, range 14.5–18.8 years, eight biologically male) completed the protocol. Average decrease in CDRS-R was 42.5% (p = 0.0004). Five (38%) adolescents met criteria for clinical response. Three responders showed sustained remission at 6-week follow-up; relapse occurred within 2 weeks for the other two responders. Ketamine infusions were generally well tolerated; dissociative symptoms and hemodynamic symptoms were transient. Higher dose was a significant predictor of treatment response. Conclusions: These results demonstrate the potential role for ketamine in treating adolescents with TRD. Limitations include the open-label design and small sample; future research addressing these issues are needed to confirm these results. Additionally, evidence suggested a dose–response relationship; future studies are needed to optimize dose. Finally, questions remain regarding the long-term safety of ketamine as a depression treatment; more information is needed before broader clinical use.